Categories Earnings, Other Industries

Earnings preview: What’s on the cards for Biocept in Q2

Biocept (NASDAQ: BIOC) is set to release its earnings results for the second quarter of 2019 on Monday after the market closes. The commercial-stage molecular oncology diagnostics company is likely to post a narrower loss backed by higher revenue.

The company’s revenue-generating efforts are focused on medical oncologists, surgical oncologists, pulmonologists, pathologists, and providing laboratory services utilizing both circulating tumor cell (CTC) and ctDNA testing. It also includes licensing and selling its proprietary testing.

The research and development expenses are expected to rise for the second quarter due primarily to costs associated with the development of new individual assays and automation, as well as validation of our Target Selector NGS Lung assay panel under the collaboration with Thermo Fisher Scientific.

diagnostics
Image for representation only. Courtesy: Michal Jarmoluk from Pixabay

Biocept is likely to see an increase in physician usage of its liquid biopsy tests for breast cancer monitoring using CTC. This quarter’s performance could be benefited by the Target Selector NGS Lung, its multi-gene liquid biopsy panel specifically developed to detect and monitor actionable biomarkers associated with lung cancer.

The company intends to grow its business by directly offering medical oncologists, surgical oncologists, pulmonologists, pathologists and other physicians its Target-Selector liquid biopsy CTC and ctDNA assays.

Also read: Progenics Q2 earnings review

Analysts expect the company to report a loss of $0.19 per share on revenue of $1.3 million for the second quarter. In comparison, during the previous year quarter, Biocept posted a loss of $2.70 per share on revenue of $822,000. The company has missed analysts’ expectations thrice in the past four quarters.

Also Read:  Domino’s stock tanks after Q3 sales, comps miss estimates

For the first quarter, Biocept reported a narrower loss helped by higher revenue as well as lower costs and expenses. Biocept accessioned 1,325 total samples in the first quarter of 2019, a 13% increase from last year, and accessioned 1,155 billable samples, up 7% from a year ago.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

CRWD Earnings: All you need to know about CrowdStrike Q1 2021 earnings results

CrowdStrike Holdings (NASDAQ: CRWD) today announced its first quarter financial results for the period ended April 30, 2020. Net loss for the first quarter was $19.2 million, or ($0.09) per

Zoom Video Communications (ZM) Q1 profit beats estimates, guides Q2 above view

Zoom Video Communications Inc. (NASDAQ: ZM) reported its financial results for the quarter ended April 30, 2020, on Tuesday after the market closes. The results exceeded analysts' expectations. The company

A visual representation of DICK’S Sporting Goods (DKS) Q1 2020 earnings results

DICK'S Sporting Goods Inc. (NYSE: DKS) slipped to a loss in the first quarter of 2020 from a profit last year, due to the impacts from temporary store closures, expenses,

Tags

Top